DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

Background Biomarkers for response prediction to anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC) are urgently needed for a personalized therapy approach. We investigated the predictive potential of inflammatory par...

Full description

Bibliographic Details
Main Authors: Matthias Preusser, Anna Sophie Berghoff, Thorsten Fuereder, Leonhard Müllauer, Gerwin Heller, Angelika Martina Starzer, Katharina Feldmann, Erwin Tomasich, Teresa Hatziioannou, Stefan Traint, Thomas Melchardt, Christoph Minichsdorfer, Ursula Schwarz-Nemec, Maja Nackenhorst
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e003420.full

Internet

https://jitc.bmj.com/content/10/3/e003420.full

Similar Items